|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Human breast cancer MCF-7 cells|
|Storage buffer||PBS, pH 7.4|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunocytochemistry (ICC)||1-10 ug/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||1-10 ug/ml|
|Immunoprecipitation (IP)||1-4 ug/ml|
|Western Blot (WB)||1-4 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody will not cross-react with rat.
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Co-existence of epithelioid and fibroblastoid subsets in a sarcomatoid renal carcinoma cell line revealed by clonal studies.
MA1-10196 was used in flow cytometry to study the presence in a sarcomatoid renal carcinoma cell line of both epithelioid and fibroblastoid cells
|Hsieh CH,Chen HC,Chang YH,Pang ST,Kuo ML,Chuang CK,Liao SK||Anticancer research (33:4875)||2013|
Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers.
MA1-10196 was used in flow cytometry to evaluate the Ep-CAM genetic vaccination strategy in animal models
|Elia L,Mennuni C,Storto M,Podda S,Calvaruso F,Salucci V,Aurisicchio L,Scarito A,Ciliberto G,La Monica N,Palombo F||European journal of immunology (36:1337)||2006|
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
MA1-10196 was used in immunocytochemistry to develop a process involving leukapheresis, elutriation and FACS to isolate circulating tumor cells from large volumes
|Eifler RL,Lind J,Falkenhagen D,Weber V,Fischer MB,Zeillinger R||Cytometry. Part B, Clinical cytometry (80:100)||2011|
Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation.
MA1-10196 was used in immunocytochemistry to study the role of adhesion-dependent regulation of PERK activity in modulating mammary acinar morphogenesis and breast tumorigenesis via inhibition of proliferation
|Sequeira SJ,Ranganathan AC,Adam AP,Iglesias BV,Farias EF,Aguirre-Ghiso JA||PloS one (2:null)||2007|
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
MA1-10196 was used in immunohistochemistry to study the therapeutic implications of epithelial cell adhesion molecule overexpression in epithelial ovarian carcinomas
|Bellone S,Siegel ER,Cocco E,Cargnelutti M,Silasi DA,Azodi M,Schwartz PE,Rutherford TJ,Pecorelli S,Santin AD||International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (19:860)||2009|
|Not Applicable||Not Cited||
Gradients in the liver's extracellular matrix chemistry from periportal to pericentral zones: influence on human hepatic progenitors.
MA1-10196 was used in immunohistochemistry to identify key matrix components required for ex vivo maintenance of human hepatic progenitors
|McClelland R,Wauthier E,Uronis J,Reid L||Tissue engineering. Part A (14:59)||2008|
EpCAM-specific vaccine response by modified antigen and chimeric costimulatory molecule in cynomolgus monkeys.
MA1-10196 was used in western blot to examine a novel costimulatory adjuvant for tumor immuno therapy
|Neighbors M,Apt D,Chang JC,Brinkman A,Sipos-Solman I,Ong R,Leong S,Punnonen J||Journal of immunotherapy (Hagerstown, Md. : 1997) (31:644)||2008|